Related Experiment Video
Updated: Oct 19, 2025

Systems Analysis of the Neuroinflammatory and Hemodynamic Response to Traumatic Brain Injury
Published on: May 27, 2022
Coagulation profiles and viscoelastic testing in multisystem inflammatory syndrome in children
Ashish A Ankola1, Victoria R Bradford2, Jane W Newburger3
1Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Insights
Children with multisystem inflammatory syndrome (MIS-C) show hypercoagulability on thromboelastography (TEG) testing, indicating increased clot strength. Inflammatory markers like ESR and platelets correlate with clot strength, suggesting potential for thromboprophylaxis strategies.
Area of Science:
- Pediatric critical care medicine
- Hematology
- Rheumatology
Background:
- Multisystem inflammatory syndrome in children (MIS-C) is a serious condition associated with hyperinflammation and potential thrombotic complications.
- Understanding the hemostatic profile of MIS-C is crucial for guiding clinical management and preventing adverse events.
Purpose of the Study:
- To characterize the viscoelastic testing profiles of children diagnosed with MIS-C.
- To investigate the relationship between thromboelastography (TEG) parameters and inflammatory markers in MIS-C patients.
Main Methods:
- A single-center retrospective review of 30 MIS-C patients (March-September 2020).
- Thromboelastography (TEG) with platelet mapping performed in 19 patients and compared to age- and sex-matched controls.
- Correlation analysis between TEG parameters and inflammatory markers (ESR, platelet counts).
Main Results:
- MIS-C patients exhibited abnormal TEG results indicative of hypercoagulability, including increased clot formation rate and strength, and reduced fibrinolysis compared to controls.
- TEG maximum amplitude and alpha angle showed moderate correlations with erythrocyte sedimentation rate (ESR) and platelet counts.
- Prophylactic treatment with aspirin (ASA) and/or anticoagulation was administered to most patients, with no symptomatic thrombotic events or major bleeding observed.
Conclusions:
- Viscoelastic testing via TEG reveals evidence of hypercoagulability in children with MIS-C.
- Elevated ESR and platelet counts are associated with increased clot strength in these patients.
- Further multicenter studies are needed to establish optimal thromboprophylaxis algorithms for MIS-C.
Objective:
To characterize viscoelastic testing profiles of children with multisystem inflammatory syndrome in children (MIS-C).
Methods:
This single-center retrospective review included 30 patients diagnosed with MIS-C from March 1 to September 1, 2020. Thromboelastography (TEG) with platelet mapping was performed in 19 (63%) patients and compared to age- and sex-matched controls prior to cardiac surgery. Relationships between TEG parameters and inflammatory markers were assessed using correlation.
Results:
Patients with MIS-C had abnormal TEG results compared to controls, including decreased kinetic (K) time (1.1 vs. 1.7 minutes, p < .01), increased alpha angle (75.0° vs. 65.7°, p < .01), increased maximum amplitude (70.8 vs. 58.3 mm, p < .01), and decreased lysis in 30 minutes (Ly30) (1.1% vs. 3.7%, p = .03); consistent with increased clot formation rate and strength, and reduced fibrinolysis. TEG maximum amplitude was moderately correlated with erythrocyte sedimentation rate (ESR) (r = 0.60, p = .02), initial platelet count (r = 0.67, p < .01), and peak platelet count (r = 0.51, p = .03). TEG alpha angle was moderately correlated with peak platelet count (r = 0.54, p = .02). Seventeen (57%) patients received aspirin (ASA) and anticoagulation, five (17%) received only ASA, and three (10%) received only anticoagulation. No patients had a symptomatic thrombotic event. Six (20%) patients had a bleeding event, none of which was major.
Conclusions:
Patients with MIS-C had evidence of hypercoagulability on TEG. Increased ESR and platelets were associated with higher clot strength. Patients were prophylactically treated with ASA or anticoagulation with no symptomatic thrombosis or major bleeding. Further multicenter study is required to characterize the rate of thrombosis and optimal thromboprophylaxis algorithm in this patient population.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

